PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
Abstract
Authors
J Huels A Wright K Kahler M Omar RW Dubois CF Chiou OV Doan